Vanda Pharmaceuticals VNDA Q3 2025 earnings
Reported October 29, 2025 · After market close
Revenue$56.3MMiss by $3.0M
EPS-$0.38Miss by $0.07
Revenue estimate$59.3M
EPS estimate-$0.31
Next report
Jul 30, 2026 (Tomorrow)Revenue estimate$61.9M
EPS estimate-$0.58
Versus estimates
Revenue
Diluted EPS
Ask the moment Vanda Pharmaceuticals reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Vanda Pharmaceuticals report Q3 2025 earnings?
- Vanda Pharmaceuticals (VNDA) reported Q3 2025 earnings on October 29, 2025 after market close.
- What were Vanda Pharmaceuticals's Q3 2025 revenue and EPS?
- Vanda Pharmaceuticals reported revenue of $56.3M and eps of $-0.38 for Q3 2025.
- Did Vanda Pharmaceuticals beat estimates in Q3 2025?
- Revenue missed the consensus estimate of $59.3M by $3.0M. EPS missed the consensus estimate of $-0.31 by $0.07.
- How did Vanda Pharmaceuticals's Q3 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 18.1% from $47.7M a year earlier and eps declined 322.2% from $-0.09.
- Where can I find Vanda Pharmaceuticals's Q3 2025 SEC filings?
- You can read the 10-Q periodic report (0001628280-25-047317) directly on SEC EDGAR. The filing index links above go to sec.gov.